June 22, 2026 – SpaceX Sneezes, Wall Street Catches a Cold: Markets Reprice the Gravity of Lofty Valuations -( $ABBV $DIA $NOK $SMCI $SMWB Rise! )

US stocks faded into the close on Monday, June 22, 2026, as a fresh selloff in newly public SpaceX (SPCX) and pressure across mega-cap tech pulled the S&P 500 and Nasdaq off record territory, even as investors weighed progress in US‑Iran peace talks and braced for a pivotal inflation print later this week. On a positive note, the Dow managed move up .29% to close at 51,712.71.Bond markets hinted at rising rate‑hike odds under the Fed’s new leadership, keeping macro sensitivity high across growth and AI‑levered names.

Market wrap: “From melt‑up to shake‑out”

• US equities slipped after flirting with all‑time highs, with broad indices dragged lower by a sharp, renewed rout in SpaceX and a pullback in big tech leaders.
• The SpaceX slide has now extended over multiple sessions, leaving the stock more than 15% below its recent peak but still well above its IPO price, a classic post‑IPO digestion that is now bleeding into risk sentiment across high‑beta growth and space‑adjacent plays.
• Globally, optimism around potential de‑escalation in the Middle East via US‑Iran peace efforts supported risk earlier in the session, but profit‑taking into the close underscored how fragile the rally is with inflation and policy still unresolved.

Macro: peace premium vs. inflation risk

• FX and macro strategists highlighted that the US‑Iran talks in Switzerland—aimed at a durable peace framework and keeping the Strait of Hormuz open—are an under‑appreciated upside scenario for global trade and energy stability if they hold, but markets are not ready to price a full peace dividend yet.
• The US dollar index remains firm but capped, as traders look ahead to this week’s PCE inflation release, where consensus expects a re‑acceleration on both a month‑over‑month and year‑over‑year basis, a combination that could revive the “higher for longer” narrative if realized.
• Under new Fed Chair Kevin Warsh, the central bank recently left rates unchanged while emphasizing the primacy of restoring and anchoring price stability, with swaps now assigning roughly 50% odds to a 25‑bp hike as soon as September—up sharply from around 20% just a week ago.

AI and tech: agentic networks meet valuation gravity

• Beyond the day‑to‑day price action, one of the more strategic headlines is the deepening collaboration between Nokia and Google Cloud to bring agentic AI into Nokia’s (NOK, $14.43, +6.97%) Network as Code platform, effectively turning telecom networks into programmable surfaces that AI agents can tap through APIs without custom integration.
• The partnership, which builds on the launch of Nokia network APIs on Google Cloud’s marketplace, uses Google’s agent developer stack and Gemini models so that software agents can automatically select and orchestrate network functions in response to high‑level intent, closing the loop between AI decisioning and network execution.
• For investors, this positions telco infrastructure as an emergent AI platform layer: monetizable APIs, lower operational friction through predictive, automated workflows, and an expanded addressable market for both Nokia and hyperscalers targeting network‑dense use cases like IoT, edge computing, and industrial automation.

SMCI: AI hardware bellwether sends a mixed signal

• Super Micro Computer (SMCI, 435.46, +15.66%) continues to trade as a high‑beta proxy on AI server demand, with recent fundamental work modestly increasing fair‑value estimates on the back of robust AI server growth while still flagging concerns around margins, customer concentration, governance, and dilution risk.
• Technical and short‑term forecast models currently view SMCI as a “strong buy” candidate over the near term, citing several positive signals and a rising trend structure, even as moving averages and mixed signals underscore a neutral‑to‑bearish posture over longer horizons.
• In practice, SMCI sits at the crossroads of two narratives: a cyclical digestion phase for AI infrastructure after a powerful run, and a structural story of hyperscale cloud and enterprise AI deployments that may still be early in their server refresh cycles.

Biotech & immunology: AbbVie’s durability bet

• On the biotech side, recent work on AbbVie’s (ABBV, $230.01, +6.25%) more than 10 billion dollar immunology deal spree highlights big‑pharma’s willingness to pay up for durable, late‑stage biologics platforms that can extend and diversify cash flows as legacy franchises mature.
• The transactions, which span multiple counterparties and focus on advanced biologics and immunology assets, signal a competitive landscape where scale players are racing to secure multi‑billion‑dollar revenue runways in autoimmune and related inflammatory conditions.
• For sector allocators, this underlines a constructive M&A backdrop for well‑positioned, clinically de‑risked platforms in immunology and adjacent areas, even as earlier‑stage biotech remains bifurcated between well‑funded category leaders and capital‑starved laggards.

VP Watchlist Updates

Eupraxia Pharmaceuticals Inc. (EPRX, $6.64, +2,47%), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (May 5) the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). These data were also presented at the ongoing Digestive Disease Week (“DDW”) conference in Chicago. “The EREFS is an important, validated visual index of severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures and other visible markers of disease often associated with symptoms. Today’s data demonstrated improvement in two key outcomes with EP-104GI in the treatment of EoE: first, that a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus; second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub scores of EREFS was observed,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This EREFS data being reported at DDW is consistent with the improvements we have seen in EoE symptoms and tissue health (EoEHSS) and suggests improvement in inflammation, fibrosis and the associated narrowing of the esophagus.”

Modular Medical, Inc. (NASDAQ:MODD, $4.34), a leader in innovative, patient-centric insulin delivery, announced (June 4) the launch of PivotPump.com, a patient-focused website designed to support individuals seeking a simpler path to insulin pump therapy. This launch follows the Company’s receipt of U.S. Food and Drug Administration (“FDA”) clearance in April 2026 for its Pivot™ insulin delivery system. The FDA clearance represents a significant milestone in Modular Medical’s strategy to expand access to insulin pump technology, particularly among individuals historically underserved by existing solutions. The Company remains on track for commercial launch in the fall of 2026. Pivot is designed for people living with diabetes who rely on daily insulin injections, as well as those who have encountered technological, usability, or cost-related barriers with traditional pump systems. The system emphasizes simplicity and ease of use for the patient and full access to clinical information for the clinician to reduce adoption friction. The PivotPump.com website provides accessible, educational content on insulin pump therapy and highlights the Company’s focus on real-world usability and supporting patients in evaluating and adopting pump-based diabetes care.

Similarweb Ltd. (NYSE: SMWB), a leading digital data and analytics company powering critical business decisions, announced (June 15) that it has surpassed $300 million in Annual Recurring Revenue (ARR) and signed two multi-year enterprise contracts, each representing seven-figure ARR commitments. Collectively, these contracts represent approximately $47 million in Total Contract Value to be recognized over the next three years and were signed during the second quarter of 2026.

The Sources

Here are the sources referenced, in numerical order, with links:

1. Yahoo Finance – “Stock market today: S&P 500, Nasdaq, Dow futures slide as big tech, SpaceX hammered”
   https://finance.yahoo.com/markets/stocks/live/stock-market-today-sp-500-nasdaq-slide-as-big-tech-spacex-hammered-225817825.html
2. CNBC – “Stock market today: Live updates”
   https://www.cnbc.com/2026/06/21/stock-market-today-live-updates.html
3. Yahoo Finance – “Nokia, Google Cloud partner to embed AI and agentic capabilities into networks”
   https://finance.yahoo.com/technology/ai/articles/nokia-google-cloud-partner-embed-120000521.html
4. Yahoo Finance – Super Micro Computer, Inc. (SMCI) quote and profile page
   https://finance.yahoo.com/quote/SMCI/
5. Vista Partners – “Biologics Bulls and Billion-Dollar-Plus Bets: AbbVie’s Immunology $10.9B Durability Shopping Spree Explained (ABBV, APGE, EPRX, REGN, SNY)”
   https://vistapglobal.com/biologics-bulls-and-billion-dollar-plus-bets-abbvies-immunology-10-9b-durability-shopping-spree-explained-abbv-apge-eprx-regn-sny/